Attention-deficit/hyperactivity disorder is considered one of the most common neurodevelopmental disorders of childhood. Primary care providers are in the unique position of providing comprehensive care—routine care, well child visits, immunizations, and other healthcare needs—to a majority of children and adolescents with attention-deficit/hyperactivity disorder. As such, primary care providers are pivotal in the diagnosis, management, and treatment of this population. This article will address special treatment considerations to aid in the management of attention-deficit/hyperactivity disorder in the primary care setting, including substance use disorders and diversion, cardiac issues and stimulant medication, medication holidays and follow-up monitoring. The database of PubMed was searched using keywords that included attention-deficit/hyperactivity disorder, children, prevalence, medication holidays, safety, cardiovascular, cardiac, blood pressure, substance use, diversion, adverse drug reactions; inclusion dates were January 1, 2011 to September 30, 2015.
American Psychiatric Association Attention-deficit/hyperactivity disorder In:. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013, pp. 59–66.
HarstadELevySCommittee on substance abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics2014; 134: e293–e301.
4.
DalsgaardSLeckmanJFMortensenPB. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry2015; 2: 702–709.
5.
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines, 3rd ed. http://www.caddra.ca/practice-guidelines/download (2011, accessed 12 October 2015).
6.
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128: 1007–1022.
7.
PliszkaS. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry2007; 46: 894–921.
8.
VisserSNDanielsonMLBitskoRH. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United states, 2003–2011. J Am Acad Child Adolesc Psychiatry2014; 53: 34–46.e2.
9.
HaukL. AAP releases guideline on diagnosis, evaluation, and treatment of ADHD. Am Fam Physician2013; 87: 61–62.
10.
HolbrookJRCuffeSPCaiB. Persistence of parent-reported ADHD symptoms from childhood through adolescence in a community sample. J Atten Disord2014; 20: 11–20.
11.
VisserSNVisserSNZablotskyB. Diagnostic experiences of children with attention-deficit/hyperactivity disorder. Natl Health Stat Report2015; 3: 1–8.
12.
PolanczykGVWillcuttEGSalumGA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol2014; 43: 434–442.
13.
PolanczykGde LimaMSHortaBL. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry2007; 164: 942–948.
14.
ThomasRSandersSDoustJ. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics2015; 135: e994–e1001.
15.
MorrowRLGarlandEJWrightJM. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ2012; 184: 755–762.
FaraoneSVBuitelaarJ. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry2010; 19: 353–364.
18.
VitielloBSevereJBGreenhillLL. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry2001; 40: 188–196.
NewcornJHKratochvilCJAllenAJ. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry2008; 165: 721–730.
FaraoneSV. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord2012; 16: 128–137.
24.
MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA cooperative group. multimodal treatment study of children with ADHD. Arch Gen Psychiatry1999; 56: 1073–1086.
25.
MTA Cooperative Group. National institute of mental health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics2004; 113: 754–761.
26.
Sonuga-BarkeEJBrandeisDCorteseS. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry2013; 170: 275–289.
27.
GilliesDSinnJKLadSS. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev2012; 7: CD007986.
28.
HodgsonKHutchinsonADDensonL. Nonpharmacological treatments for ADHD: a meta-analytic review. J Atten Disord2014; 18: 275–282.
29.
CharachAYeungEClimansT. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry2011; 50: 9–21.
30.
LeeSSHumphreysKLFloryK. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev2011; 31: 328–341.
31.
HumphreysKLEngTLeeSS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry2013; 70: 740–749.
32.
SteinhausenHCBisgaardC. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol2014; 24: 232–241.
33.
ObiohaOAdesmanA. Pearls, perils, and pitfalls in the assessment and treatment of attention-deficit/hyperactivity disorder in adolescents. Curr Opin Pediatr2014; 26: 119–129.
34.
WilensTEMartelonMJoshiG. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry2011; 50: 543–553.
35.
DalsgaardSMortensenPBFrydenbergM. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood – a naturalistic long-term follow-up study. Addict Behav2014; 39: 325–328.
36.
WilensTEMorrisonNR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry2011; 24: 280–285.
37.
GroenmanAPOosterlaanJRommelseNN. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry2013; 203: 112–119.
38.
MolinaBSHinshawSPEugene ArnoldL. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry2013; 52: 250–263.
39.
McCabeSEWestBT. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. J Am Acad Child Adolesc Psychiatry2013; 52: 1272–1280.
40.
McCabeSEWestBTTeterCJ. Characteristics associated with the diversion of controlled medications among adolescents. Drug Alcohol Depend2011; 118: 452–458.
41.
Epstein-Ngo QM, McCabe SE, Veliz PT, et al. Diversion of ADHD stimulants and victimization among adolescents. J Pediatr Psychol 2015; 1--13: pii: jsv105. Epub ahead of print 19 November 2015. DOI: 10.1093/jpepsy/jsv105.
LasopaSOStrileyCWCottlerLB. Diversion of prescription stimulant drugs among 10–18-year-olds. Curr Opin Psychiatry2015; 28: 292–298.
45.
Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 2016; 173(1): 34--43.
46.
HancTSlopienAWolanczykT. Attention-deficit/hyperactive disorder is related to decreased weight in the preschool period and to increased rate of overweight in school-age boys. J Child Adolesc Psychopharmacol2015; 25: 691–700.
47.
PerrinJMFriedmanRAKnilansTK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics2008; 122: 451–453.
48.
CooperWOHabelLASoxCM. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med2011; 365: 1896–1904.
49.
FDA. FDA drug safety communication: safety review update of medications used to treat attention-deficit/hyperactivity disorder (ADHD) in children and young adults, http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm (accessed 11 October 2015).
50.
Ministerial Implementation Committee for Attention Deficit Hyperactivity Disorder in Western Australia (MICADHD) and the Telethon Institute for Child Health Research (TICHR). Raine ADHD study: long term outcomes associated with stimulant medication in the treatment of ADHD in children, https://www.health.wa.gov.au/publications/documents/MICADHD_Raine_ADHD_Study_report_022010.pdf (accessed 11 October 2015).
51.
VitielloBElliottGRSwansonJM. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry2012; 169: 167–177.
52.
GrahamJBanaschewskiTBuitelaarJ. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry2011; 20: 17–37.
CorteseSHoltmannMBanaschewskiT. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry2013; 54: 227–246.
55.
IbrahimKDonyaiP. Drug holidays from ADHD medication: international experience over the past four decades. J Atten Disord2015; 19: 551–568.
56.
Bolea-AlamanacBNuttDJAdamouM. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British association for psychopharmacology. J Psychopharmacol2014; 28: 179–203.
57.
McElligottJTLemayJRO’BrienES. Practice patterns and guideline adherence in the management of attention deficit/hyperactivity disorder. Clin Pediatr (Phila)2014; 53: 960–966.
58.
Pelham WE, Fabiano GA, Waxmonsky JG, et al. Treatment sequencing for childhood ADHD: A multiple-randomization study of adaptive medication and behavioral interventions. J Clin Child Adolesc Psycholc 2016: 1--20.
